Press Releases

Name: Medicure Inc.
Address: 1250 Waverley Street, Winnipeg, Manitoba, R3T 6C6
Price range: unknown

MEDICURE ANNOUNCES EXPANSION OF ITS PHARMACY BUSINESS THROUGH SIGNING OF A PURCHASE AGREEMENT FOR THE ACQUISITION OF GATEWAY MEDICAL PHARMACY February 18, 2025	MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2024 November 25, 2024	MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 26, 2024 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2024 AND ANNOUNCES RESIGNATION OF BOARD MEMBER November 18, 2024
MEDICURE ANNOUNCES POSITIVE SETTLEMENT OF PRODUCT DEVELOPMENT AND SUPPLY CONTRACTS October 24, 2024	MEDICURE ANNOUNCES CLOSING OF ASSET PURCHASE AGREEMENT WITH CANAM BIORESEARCH FOR ACQUISITION OF INTELLECTUAL PROPERTY August 14, 2024	MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2024 August 14, 2024
MEDICURE ANNOUNCES SIGNING OF ASSET PURCHASE AGREEMENT WITH CANAM BIORESEARCH INC. FOR ACQUISITION OF INTELLECTUAL PROPERTY June 24, 2024	MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2024 AND ANNUAL GENERAL MEETING DIRECTOR ELECTION RESULTS May 28, 2024	MEDICURE RECEIVES US FDA FAST TRACK DESIGNATION FOR MC-1 FOR PNPO DEFICIENCY April 23, 2024
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED DECEMBER 31, 2023 April 8, 2024	MEDICURE TO PRESENT FINANCIAL RESULTS ON APRIL 9, 2024 CALL at 8:30 AM ET FOR QUARTER AND YEAR ENDED DECEMBER 31, 2023 April 4, 2024	MEDICURE ANNOUNCES NEW PARTNERSHIP THROUGH ITS MARLEY DRUG SUBSIDIARY TO PROVIDE BRENZAVVY® AS AN AFFORDABLE MEDICATION FOR AMERICANS WITH TYPE 2 DIABETES December 5, 2023
MEDICURE ANNOUNCES FDA PROVIDES COMPLETE APPROVAL TO ENROLL PATIENTS IN ITS PIVOTAL PHASE 3 TRIAL FOR TREATMENT OF RARE PEDIATRIC DISEASE November 23, 2023	MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2023 November 21, 2023	MEDICURE REITERATES ITS COMMITMENT TO PROVIDING EXCEPTIONAL ACCESS TO ITS BRANDED PITAVASTATIN (ZYPITAMAG) TO PEOPLE LIVING WITH HIV August 29, 2023
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2023 July 28, 2023	MEDICURE TO PRESENT FINANCIAL RESULTS ON JULY 31, 2023 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2023 July 24, 2023	MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2023 May 26, 2023
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED DECEMBER 31, 2022 April 6, 2023	MEDICURE TO PRESENT FINANCIAL RESULTS ON APRIL 10, 2023 CALL at 8:30 AM ET FOR QUARTER AND YEAR ENDED DECEMBER 31, 2022 April 5, 2023	MEDICURE ANNOUNCES RESIGNATION OF BOARD MEMBER AND GRANT OF STOCK OPTIONS February 1, 2023
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2022 November 24, 2022	MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2022 November 17, 2022	MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2022 August 24, 2022
MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022 August 17, 2022	MEDICURE ANNOUNCES RESULTS OF 2022 AGM June 20, 2022	MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2022 AND APPOINTMENT OF HAARIS UDDIN AS CHIEF FINANCIAL OFFICER May 30, 2022
MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED DECEMBER 31, 2021 April 27, 2022	MEDICURE TO REPORT FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2021 ON APRIL 28TH AT 7:30 AM CST April 26, 2022	MEDICURE ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER AND SUCCESSION PLAN March 23, 2022
Medicure's Subsidiary - Marley Drug to Partner with RxSpark, the Next Generation in Pharmacy Discount Programs, to be its Sole Mail-Order Pharmacy February 22, 2022	Medicure Launches E-Commerce Pharmacy Platform - marleydrug.com Through its Subsidiary Marley Drug Pharmacy February 9, 2022	Medicure Plans To Launch Innovative E-Commerce Pharmacy Platform Offering Hundreds of Medications Directly To Millions of Americans November 22, 2021
Medicure Reports Financial Results for Quarter Ended September 30, 2021 November 22, 2021	Medicure Announces that the Shortened AGGRASTAT® Versus INTEGRILIN® in Percutaneous Coronary Intervention (SAVI-PCI) Study has Met its Primary Endpoint November 4, 2021	Medicure Reports Financial Results for the Second Quarter Ended June 30, 2021 August 27, 2021
Medicure Announces Grant of Stock Options July 30, 2021	Medicure Announces Appointment of David Gurvey as Chief Financial Officer June 24, 2021	Medicure Reports Financial Results for Quarter Ended March 31, 2021 May 10, 2021
Medicure 2020 Annual and Q1 2021 Results and Conference Call Date May 5, 2021	Medicure Announces Resignation of Chief Financial Officer and Succession Plan April 28, 2021	Medicure Reports Financial Results for Quarter and Year Ended December 31, 2020 April 20, 2021
Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, March 30, 2021 March 29, 2021	Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, March 9, 2021 March 8, 2021	Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, February 23, 2021 February 22, 2021
Medicure To Participate In Renmark's Virtual Non-Deal Roadshow Series on Monday, February 8, 2021 February 4, 2021	Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial of AGGRASTAT® (tirofiban hydrochloride) Injection vs. Placebo for Induced Suppression of Platelets Activity in Aneurysmal Subarachnoid Hemorrhage Managem January 27, 2021	Medicure Announces Pivotal Phase 3 Trial IND Filing with FDA for Treatment of Seizures Associated with Pyridox(am)ine 5'-phosphate oxidase (PNPO) Deficiency January 7, 2021
Medicure Enters the US Online Pharmacy World with Acquisition of Marley Drug December 17, 2020	Medicure Retains Investor Relations Firm Renmark Financial Communications Inc. December 2, 2020	Medicure Announces Settlement of Patent Infringement Action November 18, 2020
Medicure Reports Financial Results for Quarter Ended September 30, 2020 November 11, 2020	Medicure Q3 2020 Results and Conference Call Dates November 5, 2020	Medicure announces an agreement with Reliance Life Sciences for the marketing rights of a cardiovascular biosimilar October 5, 2020
Medicure Announces AGGRASTAT® Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports August 24, 2020	Medicure Announces Termination of ReDSTM Pro Marketing and Distribution Agreement August 20, 2020	Medicure Reports Financial Results for Quarter Ended June 30, 2020 August 11, 2020
Medicure Q2 2020 Results and Conference Call Dates August 5, 2020	Medicure Announces Positive Results for AGGRASTAT® in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation June 29, 2020	Medicure Announces Normal Course Issuer Bid June 29, 2020

Newer | Older

Press Releases

MEDICURE ANNOUNCES EXPANSION OF ITS PHARMACY BUSINESS THROUGH SIGNING OF A PURCHASE AGREEMENT FOR THE ACQUISITION OF GATEWAY MEDICAL PHARMACY

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2024

MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 26, 2024 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2024 AND ANNOUNCES RESIGNATION OF BOARD MEMBER

MEDICURE ANNOUNCES POSITIVE SETTLEMENT OF PRODUCT DEVELOPMENT AND SUPPLY CONTRACTS

MEDICURE ANNOUNCES CLOSING OF ASSET PURCHASE AGREEMENT WITH CANAM BIORESEARCH FOR ACQUISITION OF INTELLECTUAL PROPERTY

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2024

MEDICURE ANNOUNCES SIGNING OF ASSET PURCHASE AGREEMENT WITH CANAM BIORESEARCH INC. FOR ACQUISITION OF INTELLECTUAL PROPERTY

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2024 AND ANNUAL GENERAL MEETING DIRECTOR ELECTION RESULTS

MEDICURE RECEIVES US FDA FAST TRACK DESIGNATION FOR MC-1 FOR PNPO DEFICIENCY

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED DECEMBER 31, 2023

MEDICURE TO PRESENT FINANCIAL RESULTS ON APRIL 9, 2024 CALL at 8:30 AM ET FOR QUARTER AND YEAR ENDED DECEMBER 31, 2023

MEDICURE ANNOUNCES NEW PARTNERSHIP THROUGH ITS MARLEY DRUG SUBSIDIARY TO PROVIDE BRENZAVVY® AS AN AFFORDABLE MEDICATION FOR AMERICANS WITH TYPE 2 DIABETES

MEDICURE ANNOUNCES FDA PROVIDES COMPLETE APPROVAL TO ENROLL PATIENTS IN ITS PIVOTAL PHASE 3 TRIAL FOR TREATMENT OF RARE PEDIATRIC DISEASE

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2023

MEDICURE REITERATES ITS COMMITMENT TO PROVIDING EXCEPTIONAL ACCESS TO ITS BRANDED PITAVASTATIN (ZYPITAMAG) TO PEOPLE LIVING WITH HIV

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2023

MEDICURE TO PRESENT FINANCIAL RESULTS ON JULY 31, 2023 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2023

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2023

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED DECEMBER 31, 2022

MEDICURE TO PRESENT FINANCIAL RESULTS ON APRIL 10, 2023 CALL at 8:30 AM ET FOR QUARTER AND YEAR ENDED DECEMBER 31, 2022

MEDICURE ANNOUNCES RESIGNATION OF BOARD MEMBER AND GRANT OF STOCK OPTIONS

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2022

MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2022

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2022

MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022

MEDICURE ANNOUNCES RESULTS OF 2022 AGM

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2022 AND APPOINTMENT OF HAARIS UDDIN AS CHIEF FINANCIAL OFFICER

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED DECEMBER 31, 2021

MEDICURE TO REPORT FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2021 ON APRIL 28TH AT 7:30 AM CST

MEDICURE ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER AND SUCCESSION PLAN

Medicure's Subsidiary - Marley Drug to Partner with RxSpark, the Next Generation in Pharmacy Discount Programs, to be its Sole Mail-Order Pharmacy

Medicure Launches E-Commerce Pharmacy Platform - marleydrug.com Through its Subsidiary Marley Drug Pharmacy

Medicure Plans To Launch Innovative E-Commerce Pharmacy Platform Offering Hundreds of Medications Directly To Millions of Americans

Medicure Reports Financial Results for Quarter Ended September 30, 2021

Medicure Announces that the Shortened AGGRASTAT® Versus INTEGRILIN® in Percutaneous Coronary Intervention (SAVI-PCI) Study has Met its Primary Endpoint

Medicure Reports Financial Results for the Second Quarter Ended June 30, 2021

Medicure Announces Grant of Stock Options

Medicure Announces Appointment of David Gurvey as Chief Financial Officer

Medicure Reports Financial Results for Quarter Ended March 31, 2021

Medicure 2020 Annual and Q1 2021 Results and Conference Call Date

Medicure Announces Resignation of Chief Financial Officer and Succession Plan

Medicure Reports Financial Results for Quarter and Year Ended December 31, 2020

Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, March 30, 2021

Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, March 9, 2021

Medicure to Participate in Renmark's Virtual Non-Deal Roadshow Series on Tuesday, February 23, 2021

Medicure To Participate In Renmark's Virtual Non-Deal Roadshow Series on Monday, February 8, 2021

Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial of AGGRASTAT® (tirofiban hydrochloride) Injection vs. Placebo for Induced Suppression of Platelets Activity in Aneurysmal Subarachnoid Hemorrhage Managem

Medicure Announces Pivotal Phase 3 Trial IND Filing with FDA for Treatment of Seizures Associated with Pyridox(am)ine 5'-phosphate oxidase (PNPO) Deficiency

Medicure Enters the US Online Pharmacy World with Acquisition of Marley Drug

Medicure Retains Investor Relations Firm Renmark Financial Communications Inc.

Medicure Announces Settlement of Patent Infringement Action

Medicure Reports Financial Results for Quarter Ended September 30, 2020

Medicure Q3 2020 Results and Conference Call Dates

Medicure announces an agreement with Reliance Life Sciences for the marketing rights of a cardiovascular biosimilar

Medicure Announces AGGRASTAT® Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports

Medicure Announces Termination of ReDSTM Pro Marketing and Distribution Agreement

Medicure Reports Financial Results for Quarter Ended June 30, 2020

Medicure Q2 2020 Results and Conference Call Dates

Medicure Announces Positive Results for AGGRASTAT® in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation

Medicure Announces Normal Course Issuer Bid

Stay Connected

Sign up for our newsletter

About

Products

News and Media

Investors

Online Pharmacy

Contact Us